NASDAQ:IOBT

Io Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy IOBT

*Your capital is at risk

$0.0480

+0 (+0%)

At Close: Jun 23, 2026

IO Biotech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.47. In total, the insiders bought 93.25M and sold 2.79M IOBT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.47
● Buy	93.25M shares
● Sell	2.79M shares
92% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Jun 22, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 94.47. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Ahmad Qasim Iftikhar Chief Medical Officer	Officer	280 000 Value: $462.0K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Burkavage Brian Chief Accounting Officer	Officer	50 000 Value: $82.5K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Smith Devin Whittemore General Counsel	Officer	185 000 Value: $305.3K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Sullivan Amy Chief Financial Officer	C-Suite Officer	280 000 Value: $462.0K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Zocca Mai-britt Chief Executive Officer	CEO / President	750 000 Value: $1.24M
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Zocca Mai-britt Chief Executive Officer	CEO / President	750 000 Value: $1.24M
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Sullivan Amy Chief Financial Officer	C-Suite Officer	280 000 Value: $462.0K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Smith Devin Whittemore General Counsel	Officer	185 000 Value: $305.3K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Burkavage Brian Chief Accounting Officer	Officer	50 000 Value: $82.5K
Mar 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Ahmad Qasim Iftikhar Chief Medical Officer	Officer	280 000 Value: $462.0K
Feb 09, 2024 Sell	COMMON STOCK S-Sale	Novo Holdings A/s 10 Percent Owner	10% Owner	658 809 Value: $988.4K
Feb 09, 2024 Sell	COMMON STOCK S-Sale	Novo Holdings A/s 10 Percent Owner	10% Owner	658 809 Value: $988.4K
Nov 22, 2023 Buy	Common Stock P-Purchase	Burkavage Brian Chief Accounting Officer	Officer	5 000 Value: $5K
Nov 22, 2023 Buy	Common Stock P-Purchase	Burkavage Brian Chief Accounting Officer	Officer	5 000 Value: $5K
Nov 21, 2023 Buy	Common Stock P-Purchase	Burkavage Brian Chief Accounting Officer	Officer	5 000 Value: $5K
Nov 21, 2023 Buy	Common Stock P-Purchase	Burkavage Brian Chief Accounting Officer	Officer	5 000 Value: $5K
Nov 15, 2023 Buy	Stock Option (Right to Buy) A-Award	Collins Helen Louise Director	Director	64 238 Value: $63.0K
Nov 15, 2023 Buy	Stock Option (Right to Buy) A-Award	Collins Helen Louise Director	Director	64 238 Value: $63.0K
Nov 09, 2023 Buy	Common Stock J-Other	Collins Helen Louise Insider	Other	0 Value: $0
Nov 09, 2023 Buy	Common Stock J-Other	Collins Helen Louise Insider	Other	0 Value: $0
Aug 11, 2023 Buy	Stock Option (Right to Buy) A-Award	Hunter Heidi Director	Director	64 238 Value: $117.6K
Aug 11, 2023 Buy	Common Stock J-Other	Hunter Heidi Insider	Other	0 Value: $0
Aug 11, 2023 Buy	Common Stock J-Other	Hunter Heidi Insider	Other	0 Value: $0
Aug 11, 2023 Buy	Stock Option (Right to Buy) A-Award	Hunter Heidi Director	Director	64 238 Value: $117.6K
Aug 09, 2023 Buy	Common Stock	Kurma Partners 10 Percent Owner	10% Owner	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IO BIOTECH, INC.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and ne...

Read Full Profile Here